Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHRH1SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC6A2
The experimentally established mechanism targets of Orphenadrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.71 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.71 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.71 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.71 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.71 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.71 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.71 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.71 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.71 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.52 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.52 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.52 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL4451316 | 1.00 | KDM4E (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL29369316 | 1.00 | KDM4E (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL322306 | 0.90 | LMNA (0.80) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL7914760 | 0.88 | LMNA (0.79) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Diphenhydramine SCHEMBL5678067 | 0.88 | LMNA (0.79) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840686 | 0.87 | LMNA (0.76) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840687 | 0.87 | LMNA (0.75) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL10840564 | 0.84 | LMNA (0.71) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL28727 | 0.84 | SLC6A2 (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A | |
| Orphenadrine SCHEMBL119471 | 0.84 | SLC6A2 (1.00) | KDM4ELMNACYP2D6CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1095 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626549-A1 | TREATMENT OF FIBROMYALGIA | UCB Biopharma SRL (BE) | 2025-10-08 | — | — | EP | claimed |
| US-20240293329-A1 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | COSMAXPHARMA CO.,LTD. (KR) | 2024-09-05 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024115393-A1 | TREATMENT OF FIBROMYALGIA | UCB Biopharma SRL (BE) | 2024-06-06 | — | — | WO | claimed |
| US-20240041773-A1 | POWDER MIXING DEVICE, AND USES THEREOF | UNIV CONNECTICUT (US) | 2024-02-08 | — | — | US | claimed |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20210275531-A1 | PHOSPHODIESTERASE-5 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2021-09-09 | — | — | US | claimed |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | THE DOSHISHA (JP) | 2020-04-23 | — | — | US | claimed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | claimed |
| US-6649183-B2 | Administering to a apnea disorder patient a therapeutically effective amount of R(+) ondansetron, or its hydrochloric salt, substantially free of its S(-) stereoisomer | SEPRACOR INC. | 2003-11-18 | — | — | US | claimed |
| WO-2003092633-A2 | DIFFUSION-CONTROLLED DOSAGE FORM AND METHOD OF FABRICATION INCLUDING THREE DIMENSIONAL PRINTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003051398-A1 | PARENTERAL COMPOSITION OF PARACETAMOL | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2003-06-26 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |
| US-4551473-A | Method of inhibiting snoring and obstructive sleep apnea | SCHOSSOW GEORGE W | 1985-11-05 | — | — | US | claimed |
| US-4181719-A | Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates | STERLING DRUG INC. (US) | 1980-01-01 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | TGFB1, CASP3, TGFB2 | SLC6A2 4816/4885HRH1 907/4885GRIN2D 4288/4885 |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | SLC6A2 3989/4885HRH1 3866/4885GRIN2D 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.